Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
August 02 2023 - 7:30AM
Cognition Therapeutics, Inc. (Nasdaq:
CGTX), a clinical-stage neuroscience company
developing drugs that treat neurodegenerative disorders by
regulating cellular damage response pathways (the “Company” or
“Cognition”), today announced that the Company will release
financial results for the second quarter on Tuesday, August 8, 2023
before the market opens. Following the release, management will
host a conference call at 8:00 a.m. ET on the same day to review
financial results and provide a business update.
Conference Call Information:
Telephone Access: |
US/New York Participant Dial-in Number: (646) 307-1963US/Canada
Participant Toll-Free Dial-in Number: (800) 715-9871Conference ID
Number: 8093818 |
|
|
Webcast
Access: |
A live webcast can be accessed
here: https://edge.media-server.com/mmc/p/uk2ydsta or on the
Investors Relations section of the company website under News &
Events. An archive of the webcast will be available for 90 days
beginning at approximately 10:00 a.m. ET, on Tuesday,
August 8, 2023. |
About Cognition Therapeutics: Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical
programs in Alzheimer’s disease, dementia with Lewy bodies
(DLB) and dry age-related macular degeneration (dry AMD). We
believe CT1812 and our pipeline of σ-2 receptor modulators can
regulate pathways that are impaired in these diseases. We believe
that targeting the σ-2 receptor with CT1812 represents a mechanism
functionally distinct from other current approaches in clinical
development for the treatment of degenerative diseases. More about
Cognition Therapeutics and its pipeline can be found
at https://cogrx.com/.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements
of historical facts or statements that relate to present facts or
current conditions, are forward-looking statements. These
statements, including statements relating to the timing and
expected results of our clinical trials, and cash runway, involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our business, financial condition, and results
of operations. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, some of which cannot be
predicted or quantified and some of which are beyond our control.
Factors that may cause actual results to differ materially from
current expectations include, but are not limited to: competition;
our ability to secure new (and retain existing) grant funding; our
ability to grow and manage growth, maintain relationships with
suppliers and retain our management and key employees; our ability
to successfully advance our current and future product candidates
through development activities, preclinical studies and clinical
trials and costs related thereto; uncertainties inherent in the
results of preliminary data and pre-clinical studies being
predictive of the results of clinical trials; the timing, scope and
likelihood of regulatory filings and approvals, including
regulatory approval of our product candidates; changes in
applicable laws or regulations; the possibility that the we may be
adversely affected by other economic, business or competitive
factors, including ongoing economic uncertainty; our estimates of
expenses and profitability; the evolution of the markets in which
we compete; our ability to implement our strategic initiatives and
continue to innovate our existing products; our ability to defend
our intellectual property; the impact of the ongoing COVID-19
pandemic on our business, supply chain and labor force; and the
risks and uncertainties described in the “Risk Factors” section of
our annual and quarterly reports filed the Securities Exchange
Commission. These risks are not exhaustive and we face both known
and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. Moreover,
we operate in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact Information: Cognition
Therapeutics, Inc. info@cogrx.com Aline Sherwood
(media) Scienta
Communications asherwood@scientapr.com Daniel
Kontoh-Boateng (investors) Tiberend Strategic Advisors,
Inc. dboateng@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From May 2023 to May 2024